Ecnoglutide

Ecnoglutide (its development name is XW003) is an injectable drug for type 2 diabetes and weight loss. It belongs to the same broad family of medicines as semaglutide — the GLP-1 receptor agonists (drugs that copy a natural gut hormone to lower blood sugar and curb appetite). Two things make it stand out. First, its makers engineered it to be “cAMP-biased,” which is a real, measured property (more on that below). Second, unlike a lot of hyped-up new compounds, it actually has large, peer-reviewed Phase 3 trials (the big, late-stage human studies regulators rely on) and real approval. The catch: that approval is in China only, all the key data come from Chinese study participants, and the marketing claim that the cAMP bias makes it clinically better than today’s drugs has never been tested directly against them in people.

What it is

Ecnoglutide is a once-weekly injection given subcutaneously (under the skin). It is a peptide — a short chain of natural amino acids (the building blocks of proteins). The molecule has been tweaked in two ways: one amino acid was swapped (an Ala8→Val8 substitution), and an 18-carbon fatty acid was attached at one spot (Lys30). That fatty acid lets the drug grab onto albumin, a protein in the blood, so it sticks around for days. The result is a half-life (the time it takes for the amount in your body to drop by half) of roughly 124-138 hours — long enough to dose just once a week.

The headline feature is “signaling bias.” When the GLP-1 receptor (the docking point on a cell that this drug switches on) gets activated, it can set off several different chains of events inside the cell. Ecnoglutide is designed to mostly trigger one of them — a messenger called cAMP — while mostly leaving two others alone (β-arrestin recruitment and receptor internalization, which is the cell pulling the receptor inside itself). In lab dish tests, it switched on cAMP very strongly (a reported EC50, a measure of potency, of about 0.018 nM) without pulling the receptor inside. The idea behind this is that keeping receptors out on the cell surface should keep the insulin-releasing and metabolic effects going strong and steady. The bias itself is genuine and was documented in the discovery paper. But whether that actually produces better results in patients than ordinary, unbiased drugs is still just a hypothesis — not something that has been proven.

The claims

The compound gets talked up as a “next-generation” GLP-1 whose cAMP bias supposedly makes it better than semaglutide and tirzepatide, and as a powerful drug for both weight loss and diabetes. Its approved, well-studied uses are controlling blood sugar in type 2 diabetes and long-term weight management in people who are overweight or obese. The shakier, more speculative versions of the story treat the bias mechanism as a proven clinical edge, and treat any version you can buy online as if it were the same thing as the approved Chinese product.

There is also a separate myth worth flagging, because it keeps popping up on some third-party sites: the claim that GLP-1 drugs were moved into a banned “S4” category on the 2026 anti-doping list. That is false (see Legal and regulatory status below).

What the evidence actually shows

The human data here are real and, by gray-market standards, unusually solid — several randomized trials, several of them published in major peer-reviewed journals. The recurring limitation is simple: nearly all of the key data come from Chinese participants, in trials connected to the company that makes the drug.

The main obesity trial is called SLIMMER (study ID NCT05813795). It was a large, well-controlled study — randomized, double-blind, and placebo-controlled (meaning people were assigned to groups by chance, neither they nor their doctors knew who got the real drug, and some got an inactive injection for comparison). It ran in 664 Chinese adults with overweight or obesity across 36 sites, testing once-weekly ecnoglutide at 1.2, 1.8, and 2.4 mg against placebo (published in The Lancet Diabetes & Endocrinology, 2025). Two different numbers are worth keeping straight here, because earlier write-ups have mixed them up. One is the weight loss beyond what placebo achieved — at week 40 that was about −9.1% (1.2 mg), −10.9% (1.8 mg), and −13.2% (2.4 mg). The other is the average total weight lost from the starting point, which at week 48 reached roughly −15.4% on the highest dose (the company’s press release cites about 15.1% placebo-adjusted at the top dose). Across the doses, between 77.7% and 92.8% of people lost at least 5% of their body weight, compared with 16% on placebo. Higher doses gave more weight loss, and the curve reportedly hadn’t flattened out yet. Most side effects were mild-to-moderate stomach and gut problems.

On the diabetes side, a Phase 2 trial (Chinese registry ID CTR20211014, not a US-style NCT number; 145 people randomized, 20 weeks; Nature Communications, 2024) reported drops in HbA1c — a blood test that reflects average blood sugar over about three months — of −1.81% (0.4 mg) to −2.39% (1.2 mg), versus −0.55% on placebo, with modest weight change. The main Phase 3 diabetes trial, EECOH-1 (NCT05680155; 211 people randomized, a 24-week double-blind portion plus a 28-week extension; Nature Communications, 2026), found HbA1c drops of −1.96% (0.6 mg) and −2.43% (1.2 mg) versus −0.87% on placebo, weight losses of around −3.0 to −3.2 kg, and up to about 80% of people getting their HbA1c below 7%. There was also a separate Phase 2b obesity trial in Australia and New Zealand (around 206 participants, 26 weeks, compared against liraglutide 3.0 mg, another GLP-1 drug) that reported strong weight loss — but it only exists as a 2022 company press release, so it counts for less than the peer-reviewed Phase 3 work.

Two points deserve plain honesty. First, the discovery paper’s report that ecnoglutide caused more weight loss than semaglutide came from rodents, not from a human comparison — and there has been no head-to-head trial in people against semaglutide or tirzepatide. So the claim that the cAMP-biased design is clinically better remains unproven in humans. Second, there is no credible evidence that ecnoglutide builds muscle. Like other GLP-1 drugs, some of the weight it takes off is lean mass (muscle), and there is no human muscle or performance data for ecnoglutide specifically — the evidence there is thin to nonexistent.

Legal and regulatory status

In China, the NMPA (the country’s drug regulator) approved ecnoglutide injection for blood-sugar control in adults with type 2 diabetes on 30 January 2026, and for long-term weight management in adults with overweight or obesity on 6 March 2026. The developer calls it the world’s first approved cAMP-biased GLP-1 receptor agonist. A China-only commercialization deal with Pfizer China was announced on 24 February 2026 (Sciwind keeps manufacturing and stays the marketing-authorization holder; Pfizer gets the rights to sell it in Mainland China; the deal is worth up to roughly $495M in milestone payments).

In the United States, ecnoglutide is not FDA-approved. We found no US registration trial results and no FDA filing, and the Pfizer deal is explicitly for China only — so any US or worldwide availability should be treated as not established. Any “research-grade” or gray-market version sold outside the approved Chinese product is not an approved drug anywhere, is not quality-controlled, and is not legal for human use in the US or EU.

For athletes: GLP-1 receptor agonists are not banned by WADA (the World Anti-Doping Agency). They sit on the WADA Monitoring Program — semaglutide was added in 2024 and tirzepatide for 2026, with the whole GLP-1 class carried into the 2026 in- and out-of-competition Monitoring Program (effective 1 January 2026, and applied at the 2026 Winter Olympics). Monitoring just means WADA is watching for patterns of misuse — it is not a ban, and it does not require a therapeutic use exemption (special permission to use a medicine). WADA has hinted it might make a listing decision later (expected around end-2026 or 2027, ahead of LA 2028), but as of June 2026 GLP-1 drugs remain allowed. By extension, ecnoglutide would fall into the same monitored category, not a banned one. The third-party claim that GLP-1 drugs were moved into a banned “S4” class in 2026 is false and contradicted by WADA’s own documents. For a useful contrast: growth factors such as IGF-1 and mechano-growth factor (MGF) are banned under S2 (specifically S2.3, Growth Factors) at all times — but ecnoglutide is a GLP-1 analog, not a growth factor, so that ban does not apply to it.

Safety

The most consistent finding across the trials is dose-dependent gut side effects — nausea, diarrhea, and constipation — the usual story for this class of drug, mostly mild to moderate, and in the published studies few people quit over them. Mild hypoglycemia (low blood sugar) was uncommon and mostly showed up in the diabetes studies; no severe low blood sugar, no pancreatitis (inflammation of the pancreas), and no deaths were reported in the published trials.

Beyond what these specific trials measured, the wider GLP-1 drug class comes with label-level cautions that are reasonable to expect here too but have not all been confirmed for ecnoglutide on its own: a boxed warning (the FDA’s strongest warning) about a thyroid tumor signal seen in rodents — specifically C-cell, or medullary, tumors — which is why the class is not recommended for people with a personal or family history of medullary thyroid cancer or a condition called MEN2; plus reported risks of pancreatitis, gallbladder problems, loss of muscle mass, and weight coming back after stopping. Long-term safety, and safety in non-Chinese populations, is limited for ecnoglutide specifically — the main trials were mostly in Chinese participants, with the Phase 2b obesity study run in Australia and New Zealand. None of this is medical advice.

Bottom line

Ecnoglutide has a genuinely strong, peer-reviewed human track record — main Phase 3 trials in both obesity and diabetes published in major journals, plus real regulatory approval — which puts it well ahead of the typical gray-market peptide. It still doesn’t reach our “Strong” (grade 8–10) grade, though, for three reasons: all the key efficacy data come from Chinese participants only; the approval is China-only, with no FDA approval and no US program we could find; and the marquee selling point — that the cAMP-biased design makes it clinically better than semaglutide or tirzepatide — has never been tested head-to-head in humans. The weight-loss numbers are real but need to be read carefully (the “beyond placebo” figure and the “total from baseline” figure are different things), and there’s no evidence it builds muscle. Anything sold online outside the approved Chinese product is unapproved and unverified.

Evidence grade: 7/10 · Moderate.

Sources

• Ji L, et al. Phase 3 obesity trial (SLIMMER), NCT05813795. The Lancet Diabetes & Endocrinology. 2025. PMID 40555243.
• Ecnoglutide Phase 2 in type 2 diabetes (registry CTR20211014). Nature Communications. 2024. PMID 39333121.
• Ecnoglutide Phase 3 in type 2 diabetes (EECOH-1), NCT05680155. Nature Communications. 2026. PMID 41501026.
• Guo W, et al. Discovery of ecnoglutide — a novel, long-acting, cAMP-biased GLP-1 analog. Molecular Metabolism. 2023;75:101762.
• Sciwind Biosciences. NMPA approval for chronic weight management (6 March 2026). PR Newswire.
• Sciwind Biosciences. NMPA approval for adult type 2 diabetes (30 January 2026). PR Newswire.
• Sciwind Biosciences. Positive interim Phase 2b obesity results for XW003 (2022). PR Newswire.
• Sciwind Biosciences partners with Pfizer China to commercialize its biased GLP-1 in China (24 February 2026). PR Newswire.
• WADA publishes the 2026 Prohibited List. World Anti-Doping Agency.
• WADA’s 2026 Prohibited List now in force. World Anti-Doping Agency.
• WADA 2026 Monitoring Program (PDF). World Anti-Doping Agency.
• GLP-1RAs Monitored at the 2026 Winter Olympics. EMJ.